Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock
Launched by KINGMAN REGIONAL MEDICAL CENTER · Nov 3, 2023
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating the effects of angiotensin-II, a medication used as a second treatment for patients experiencing septic shock, a serious condition caused by infections that can lead to dangerously low blood pressure. The study aims to determine how effective angiotensin-II is when added to norepinephrine, which is the primary medication used to help raise blood pressure. Researchers believe that starting angiotensin-II earlier may be more beneficial, but they want to gather more data to understand how and when to use it best.
To be eligible for this trial, patients must be 18 years or older and have been admitted to the intensive care unit (ICU) within 12 hours of arriving at the emergency department with septic shock. They should be receiving norepinephrine to help manage their blood pressure but still need additional support. Participants can expect to receive careful monitoring and follow-up during the study. It’s important to note that those with certain conditions, such as significant bleeding issues or those requiring higher doses of norepinephrine, would not be able to participate.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients admitted to the ICU within 12 hours of presentation to the emergency department for septic shock requiring 15-25 mcg/min of norepinephrine. Septic shock will be defined as having a known or presumed infection with two or more criteria of systemic inflammatory response syndrome, a mean arterial pressure \<65 mm Hg despite fluid resuscitation requiring vasopressor support, and a serum lactate \>2 mmol/L. Criteria of systemic inflammatory response syndrome include a temperature \>100.4°F or \<96.8°F; heart rate \>90/min; respiratory rate \>20/min and a white blood cell count \>12,000/mm3 or \<4,000/mm3.
- Exclusion Criteria:
- • Age \<18 years
- • Pregnancy or lactation
- • Known allergic reactions to angiotensin-II or hydrocortisone sodium succinate
- • Requiring \>25 mcg/min of norepinephrine or on any vasopressor other than norepinephrine at study enrollment
- • Clinically significant bleeding precluding the use of chemical prophylaxis for venous thromboembolism
- • Treatment with another investigational drug or other intervention during study timeframe
About Kingman Regional Medical Center
Kingman Regional Medical Center (KRMC) is a leading healthcare provider in northern Arizona, dedicated to delivering high-quality medical services and advancing clinical research. With a commitment to innovation and patient-centered care, KRMC actively participates in clinical trials that aim to improve treatment outcomes and enhance the understanding of various medical conditions. The center is equipped with state-of-the-art facilities and a team of experienced healthcare professionals who collaborate to ensure the safety and well-being of trial participants while contributing to the advancement of medical science. Through its robust research programs, KRMC strives to provide cutting-edge therapies and improve healthcare delivery in the community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kingman, Arizona, United States
Patients applied
Trial Officials
Tyson Dietrich, PharmD
Principal Investigator
Kingman Regional Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported